High-dose chemotherapy with hematopoietic stem cell support in patients with advanced epithelial ovarian cancer: Analysis of 67 patients treated in a single institution

Anticancer Research

Volumn 19, Issue 2 B, 1999, Pages 1455-1461

  Bertucci, F ^a   Viens, P ^a   Gravis, G ^a   Blaise, D ^a   Faucher, C ^a   Oziel Taoeb, S ^a   Bardou, V J ^a   Jacquemier, J ^a   Delpero, J R ^a   Maraninchi, D ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Hematopoietic rescue; High dose chemotherapy; Ovarian cancer

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DIAZEPAM; ETOPOSIDE; MELPHALAN; THIOTEPA;

ADULT; ADVANCED CANCER; APLASIA; ARTICLE; BACTEREMIA; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; EPITHELIUM; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; FEMALE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 0033023475     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 329(21): 1550-1559, 1993.
2. Ozols RF, Young RC: Chemotherapy of ovarian cancer. Semin Oncol 18(3): 222-232, 1991.
3. Kotz KW, Schilder RJ: High-dose chemotherapy and hematopoietic progenitor cell support for patients with epithelial ovarian cancer. Semin Oncol 22, 3: 250-262, 1995.
4. Philip T, Amitage J O, Spitzer G, Chauvin F, Jagannath S, Cahn JCP, Goldstone A, Gorin N, Flesh M, Laporte JMD, Pico J, Bosly A, Anderson C, Schots R, Biron P, Cabanillas F, Dicke K: High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade or high grade non Hodgkin's lymphoma. N Engl J Med 316: 1493-1498, 1987.
5. Frei E, Antman B, Teicher B, Eder P, Schnipper L. Bone marrow autotransplantation for solid tumors. Prospects. J Clin Oncol 7, 4: 515-526, 1989.
6. Levin L, Hryniuk W: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5: 756-767, 1987.
7. Bolis G, Villa A, Guarnerio P, Ferraris C, Gavoni N, Giardina G, Melpignano M, Scarfone G, Zanaboni F, Parazzini F: Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy. Cancer 77: 128-131, 1996.
8. Viens P, Maraninchi D, Legros M, Oberling F, Philip T, Herve P, Plagne R, Dufour P, Bergerat JP, Guastalla JP, Rozenbaum A, Carcassonne Y: High-dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinoma: a retrospective analysis of 35 patients treated in France. Bone Marrow Transplant 5: 227-233, 1990.
9. Ibrahim A, Zambon E, Bourhis JH, Ostronoff M, Beaujean F, Viens P, Lhomme C, Chazard M, Maraninchi D, Hayat M et al: High-dose chemotherapy with etoposide, cyclophosphamide and escalating dose of carboplatin followed by autologous bone marrow transplantation in cancer patients. A pilot study. Eur J Cancer 29A(10): 1398-1403, 1993.
10. Thomas E D, Storb R: Technique of human marrow grafting. Blood 36: 507-515, 1970.
11. Chabannon C, Le Corroller A G, Faucher C, Novakovitch G, Blaise D, Mottai J P, Maraninchi D, Mannoni P: Patient condition affects the collection of peripherical blood progenitors after priming with recombinant granulocyte colony stimulating factor. J Hematotherapy 4: 171-179, 1995.
12. Maraninchi D, Abecassis M, Gastaut JA et al: High-dose melphalan with autologous bone marrow rescue for the treatment of advanced adult solid tumors. Cancer Treat Rep 68: 471-474, 1984.
13. WHO handbook for reporting results of cancer treatment. WHO offset publication, no. 48: Geneva, Switzerland, 1993.
14. Viens P, Maraninchi D: High-dose chemotherapy and autologous marrow transplantation for common epithelial ovarian carcinoma. In: High-dose cancer therapy. Pharmacology, Hematopoietins, stem cells (Armitage JO, Antman K.H, eds) Baltimore, Pine JW 847-854, 1995.
15. Schmitz N, Dreger P, Zander A et al: Randomized, controlled, multicentre study of granulocyte colony stimulating factor (Filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood 82: 146a (abstr. 568), 1993.
16. Stahel RA, Jost LM, Cerney T, Picher TG, Honegger H, Tobler A, Jacky E, Fey M, Platzer E: A randomized study of recombinant human granulocyte colony-stimulating factor after high dose chemotherapy and autologous bone marrow transplantation for high risk lymphoid malignancies. J Clin Oncol 12: 1931-1938, 1994.
17. Faucher C, Le Coroller AG, Blaise D, Novakovitch G, Mannoni P. Moatti JP, Maraninchi D: Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow autotransplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 14: 895-910, 1994.
18. Christian MC, Trimble EL: Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 55: S143-S150, 1994.
19. Carmichael J, Gordon A, Malfetano J et al: Topotecan, a new active drug, vs paclitaxel in advanced ovarian carcinoma: international topotecan study group trial. Proc Am Soc Clin Oncol 765, 1996.
20. Ellis ED, Williams SF, Moormeter JA: A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies. Bone Marrow Transplant 6: 439-442, 1990.
21. Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E, Henner WD: A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 7: 651-61, 1989.
22. Shea TC, Storniolo AM, Mason JR, Newton B, Mullen M, Hunger K: High-dose intrayenous (IV) and intraperitoneal (IP) combination chemotherapy with autologous stem cell rescue for patients with advanced ovarian cancer. Proc Am Soc Clin Oncol (abstr), 11: 236, 1992.
23. Broun E.R, Belinson JL, Berek JS, Mcintosh D, Hurd D, Ball H, Williams S: Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: a Gynecologic Oncology Group Pilot Study. Gynecol Oncol 54: 142-146, 1994.
24. Stiff P, Bayer R, Camarda M, Tan S, Dolan J, Potkul R, Loutfi S, Kinch L, Sosman J, Peace D, Rad N, McKenzie RS: A phase II trial of high-dose mitoxantrone, carboplatin and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. Gynecol Oncol 57: 278-285, 1995.
25. Mulder POM, Willemse PHB, Aalders JG, De Vries EGE, Sleijfer DTH, Smit Sibinga C.TH, Mulder NH: High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer. Eur J Cancer Clin Oncol 25 (4): 645-649, 1989.
26. Lotz JP, Bouleuc C, Andre T, Touboul E, Macovei C, Hannoun L, Lefranc JP, Houry S, Uzan S, Izrael V: Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. Cancer 77: 2550-9, 1996.
27. Shpall EJ, Clarke-Pearson D, Soper JT, Berchuch JT, Jones RB, Bastr C, Ross M, Lidory Y, Vanacek K, Tyler T, Peters WP: High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 38: 386-391, 1990.
28. Mc Kenzie RS, Alberts DA, Bishop MR et al: Phase I trials of high-dose Cyclophosphamide (CY), Mitoxantrone (MX), and Carboplatin (CB) with autologous bone marrow transplantation (ABMT) in female malignancies: pharmacologic levels of mitoxantrone and high response rate in refractory ovarian cancer. Proc Am Soc Clin Oncol 10: 186 (Abst. 605), 1991.
29. Mc Guire WP, Hoskins WJ, Brady MF, Krucera PR, Partridge EE, Look KY, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage 3 and 4 ovarian cancer. N Engl J Med 334: 1-6, 1996.
30. Kohn E C, Sarozy G, Bicher A, Link C, Christian M, Steinber GSM, Rothenberg GM, Adamo DO, Davis P, Ognibene FP, Cunnion RE, Reed E: Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86: 18-24, 1994.
31. Fennelly D, Schneider J, Spriggs D, Bengala C, Hakes T, Reich L, Barakat R, Curtin J, Moore MAS, Hoskins W, Norton L, Crown J: Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 5: 1160-1166, 1995.
32. Benedetti P, Panici P, Greggi S, Scambia G, Salerno MG, Menichella G, Pierelli L, Foddai ML, Bizzi B, Mancuso S: High-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Annals of Medicine 27(1): 133-8, 1995.
33. Crown J, Wassherheit C, Hakes T, Fennelly D, Reich L, Moore M, Schneider J: Rapid delivery of multiple high-dose chemotherapy courses with granulocyte collony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells. J Natl Cancer Inst 84: 1935-1936, 1992.